Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study.

Benzodiazepine and related drug use was associated with an increased risk of death in persons with AD. Our results support treatment guidelines stating that nonpharmacological approaches should be the first-line option for symptomatic treatment of AD.